① Huishang Bank's net profit exceeded 16.9 billion yuan in 2025; what is the growth rate? ② Wasion Holdings' annual profit increased by more than 40% year-over-year; what is the scale?
Cailian Press, March 6 (Editor: Feng Yi) Cailian Press brings you today's key announcements for Hong Kong stocks.
1) Earnings Highlights
Huishang Bank (03698.HK): Revenue reached 37.67 billion yuan in 2025, an increase of approximately 1.2% year-over-year; net profit was approximately 16.93 billion yuan, an increase of approximately 6.3% year-over-year.
Wasion Holdings (03393.HK): Expected to achieve a consolidated net profit of approximately 1 billion to 1.06 billion yuan in 2025, representing a year-over-year increase of approximately 42% to 50%. This is mainly attributed to increased sales revenue and effective cost control measures.
Aux Electrical (02580.HK): Expected revenue in 2025 to be approximately 30 billion yuan, with a net profit of 2.2 billion yuan, compared to 2.91 billion yuan in the same period last year. The decline is primarily due to persistently rising raw material prices, high channel inventory levels, and weak terminal consumer demand.
Yuan Shengtai Dairy (01431.HK): Expected net profit in 2025 to range between 520 million and 570 million yuan. The increase is mainly driven by higher sales volumes and reduced feed costs for dairy cows.
Duoxiang Cloud (06696.HK): Anticipated loss for the 2025 fiscal year to be no less than 270 million yuan, compared to a loss of 186 million yuan in the same period last year. The increase in losses is primarily due to higher sales costs and increased administrative expenses.
Lihong Inspection (01586.HK): Issued a profit warning, expecting the attributable profit for the year to decrease by approximately 45% to 55%.
Dayu Financial (01073.HK): Expected net profit after tax in 2025 to be approximately 37 million Hong Kong dollars.
Qingjian International (01240.HK): Expected net profit in 2025 to be no less than 60 million Hong Kong dollars.
ZhiXing Technology (01274.HK): Anticipates a pre-tax loss of approximately RMB 415 million for the fiscal year 2025, representing an increase of about 44% year-on-year. This is mainly due to pricing strategies and product mix adjustments, which led to a decline in SupervisionTM sales revenue.
Mobi Development (00947.HK): Issued a profit warning, expecting a consolidated net loss of approximately RMB 90 million to RMB 100 million for the year, marking a year-on-year decrease.
Shangmei Shares (02145.HK): Announced positive earnings forecast, projecting a profit of approximately RMB 1.14 billion to RMB 1.16 billion for the fiscal year 2025, representing an increase of about 41.9% to 44.4% year-on-year.
Solomon Semiconductor (02878.HK): Issued a profit warning, anticipating consolidated profits attributable to shareholders of approximately USD 3.5 million to USD 4 million for the fiscal year 2025, marking a year-on-year decrease of about 60% to 65%.
2) Corporate News
Yuexiu Property (00123.HK): Accumulated contract sales amounted to RMB 7.106 billion in the first two months, reflecting a year-on-year decrease of approximately 44.6%.
Poly Real Estate Group (00119.HK): Accumulated contract sales reached RMB 6 billion in the first two months, representing a year-on-year decrease of 28.57%.
Zhongliang Holdings (02772.HK): Accumulated contract sales amounted to approximately RMB 1.5 billion in the first two months, reflecting a year-on-year decrease of 35.06%.
Powerlong Real Estate (01238.HK): Accumulated contract sales amounted to RMB 901 million in the first two months, representing a year-on-year decrease of 30.69%.
China Longyuan Power (00916.HK): Accumulated power generation reached 13,535.7 GWh in the first two months, reflecting a year-on-year increase of 6.42%. Wind power generation increased by 3.04%, while solar power generation surged by 31.06% year-on-year.
Jiangshan Holdings (00295.HK): Total power generation amounted to approximately 34,820 MWh in the first two months, reflecting a year-on-year decrease of 27.69%.
Hengrui Pharma (01276.HK): Received clinical trial approval notices for Adebrelimab Injection and SHR-8068 Injection. Global sales of similar product combinations in 2024 are projected to reach approximately USD 3.271 billion.
CSPC Pharma (01093.HK): The highly selective PDE4B inhibitor (SYH2059 Inhalation Powder) has been approved for clinical trials in the United States.
Viva Biotech-B (09887.HK): The first patient has been successfully enrolled in a Phase II clinical study evaluating Velixin (PD-L1/4-1BB bispecific antibody Opatisumab, LBL-024) for the treatment of first-line esophageal squamous cell carcinoma.
Zhixing Group Holdings (01539.HK): Entered into a memorandum of understanding with Multipolar to provide high-performance computing or artificial intelligence GPU services in Indonesia.
Zhihao Holdings (01707.HK): The hearing for the winding-up petition against its subsidiary has been adjourned to April 13.
Pagate BioPharma-B (02565.HK): The first-in-human trial of Pagate Bio's next-generation GLP-1 (CR059) has yielded one-month clinical observation results.
Montage Technology (06809.HK): Stabilization activities and the stabilization period have concluded.
Jinhui Holdings (00137.HK): A subsidiary plans to sell a vessel for USD 23.455 million.
3) Share Repurchase Updates
SF Holding (06936.HK): Repurchased 203,200 A-shares at a cost of RMB 7.4244 million, with repurchase prices ranging from RMB 36.48 to RMB 36.62.
Standard Chartered Group (02888.HK): Repurchased 872,400 shares at a cost of GBP 15.0654 million, with repurchase prices ranging from GBP 16.895 to GBP 17.585.
Xindong Co., Ltd. (02400.HK): Repurchased 110,000 shares at a total cost of HKD 7.7827 million, with repurchase prices ranging from HKD 69.1 to HKD 72.15 per share.
